US 9688748
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
granted A61KA61K2039/505A61K39/39558
Quick answer
US patent 9688748 (Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 39
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61K47/68031, A61K47/6811